Abstract: A constellation of pharmacologic treatments for generalized anxiety disorder (GAD) have been developed over the past fi ve decades, although each has a number of potential drawbacks in clinical practice. This review addresses one potentially new pharmacologic treatment for generalized anxiety disorder, the gamma-aminobutyric acid analogue pregabalin. We review the mechanism of action, and pharmacokinetic and pharmacodynamic properties of pregabalin as well as the results of 5 double-blind, placebo-controlled trials of pregabalin in the treatment of generalized anxiety disorder (GAD). Based entirely on data from these industry-sponsored (Pfi zer), multi-site clinical trials in patients with GAD, pregabalin appears to be generally well tolerated and has rapid onset of action (approximately 1 week), comparable effi cacy to benzodiazepines and lower discontinuation rates compared with other pharmacologic treatments. Thus in GAD, a disorder that is often suboptimally responsive to traditional psychotherapeutic and psychopharmacologic interventions -secondary to poor effi cacy, tolerability, and/or side-effects -pregabalin may have a primary role in GAD patients, especially in those with certain psychiatric comorbidities or individuals who are on multi-drug regimens for medical comorbidities.
Introduction
With a lifetime prevalence of 4%-7% in the general population, generalized anxiety disorder (GAD) is among the most common psychiatric disorders (Kessler et al 2001) and is associated with signifi cant morbidity (World Health Organization Mental Health Survey 2004) . A constellation of pharmacologic treatments for GAD has been developed over the past 5 decades, including benzodiazepines, selective-serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SSNRIs), monoamine oxidase inhibitors, and tricyclic antidepressants. However, each of these modalities has a number of potential drawbacks in clinical practice. Benzodiazepines are associated with cognitive and motor impairment (van Laar et al 1992) , pose a signifi cant risk for dependence (Rickels et al 1990) , and interact with alcohol. The SSRIs and SSNRIs, while effi cacious in the treatment of GAD, have a delayed onset of treatment effect, are associated with sexual side-effects (Kennedy et al 2000) , and are contraindicated as monotherapy in patients with comorbid bipolar disorder (Keck et al 2006) in whom anxiety disorders commonly co-occur (McElroy et al 2001; Simon et al 2004) . Thus, there is a considerable need to expand our psychopharmacologic armamentarium. This review addresses one potentially new pharmacologic treatment for generalized anxiety disorder, the γ-aminobutyric acid analogue pregabalin, which is currently FDA-indicated for the management of neuropathic pain and post-herpetic neuralgia and for adjunctive therapy in patients with partial onset seizures.
Mechanism of action of pregabalin
Through high affi nity binding to the α 2 δ subunit of brain voltage-gated calcium channels (N-type), the γ-aminobutyric acid (GABA) analogue pregabalin ( Figure 1 ) decreases presynaptic calcium currents (Finker et al 2002) and thus decreases calcium-dependent vesicle docking at the presynaptic membrane. Since this process is fundamental for all chemical synapses, pregabalin decreases the release of various neurotransmitters which have been pathophysiolgically implicated in anxiety disorders including glutamate (Dooley et al 2000a) , substance P (Fehrenbacher et al 2003; Geracioti et al 2006) , and norepinephrine (Dooley et al 2000b; Strawn and Geracioti) . However, unlike anxiolytic compounds (eg, benzodiazepines) which exert their therapeutic effects through binding to GABA A , GABA B , and benzodiazepine receptors, pregabalin neither binds directly to these receptors nor augments GABA A currents or affects GABA metabolism (Pfi zer Inc. 2006). Moreover, pregabalin does not appear to have functional activity at serotonin, dopamine, or norepinephrine receptors and does not alter in vitro reuptake kinetics of these monoamines as do traditional antidepressant medications (eg, selective serotonin reuptake inhibitors, tricyclic antidepressants)
Pharmacokinetics of pregabalin
Highly lipophilic, pregabalin is rapidly absorbed from the gastrointestinal tract and achieves maximum plasma concentrations within 1.5 hours of oral administration and has an oral bioavailability of ≥90% (Pfi zer Inc. 2006). The C max is decreased by 25%-30% when pregabalin is taken with food but "has no clinically relevant effect on total absorption" (Pfi zer Inc. 2006) and can therefore be taken with or without food. Because of the lipophilic properties related to substitution at the 3 position of the GABA molecule, pregabalin is thought to rapidly penetrate the central nervous system in humans based on cerebrospinal fl uid and blood-brain barrier studies in lower animals (Feng et al 2001; Pfi zer Inc. 2006 
Pre-clinical studies of pregabalin in anxiety states
Lower animal studies have suggested that pregabalin may have anxiolytic properties. For example, in rats, pregabalin dose-dependently induced anxiolytic-like effects in both the confl ict test and elevated plus maze tests compared with placebo (Field et al 2001) .
Clinical studies of pregabalin in GAD
In a 3-armed study of pregabalin for the treatment of GAD , patients receiving high dose pregabalin (600 mg/day) or lorazepam (6 mg/day) but not low-dose pregabalin (150 mg/day) signifi cantly improved compared with patients receiving placebo at 4 weeks (mean decrease in HAM-A score: 13.2 with high-dose pregabalin compared with 9.3 with placebo, p = 0.001). However, patients receiving high-dose pregabalin and lorazepam were signifi cantly more likely to discontinue than those receiving low-dose pregabalin or placebo, though there was no statistically signifi cant difference between the adverse events in patients treated with high-dose pregabalin compared with those receiving lorazepam . Pande et al (2003) evaluated two doses of pregabalin (50 mg tid and 200 mg tid) in a double-blind, placebo-controlled trial which included a lorazepam arm (2 mg tid). This study consisted of a 1-week lead-in followed by 4 weeks of double blind treatment and a 1-week taper. Baseline-to-endpoint decreases in HAM-A score were signifi cantly greater than placebo for both doses of pregabalin and for lorazepam. However, this study failed to identify a statistically signifi cant difference between the two dosages of pregabalin with respect to outcome HAM-A score, nor were there signifi cant differences in HAM-A scores between patients treated with lorazepam and those treated with high-dose pregabalin.
Pohl and colleagues (2005) compared multiple pregabalin dosing regimens (100 mg bid, 200 mg bid, 150 mg tid) in a double-blind, placebo-controlled trial in GAD and found that all three pregabalin groups had improvement in HAM-A scores compared with placebo. As with previous studies in this population, pregabalin was generally well tolerated. Rickels et al (2005) , examined 3 doses of pregabalin (300 mg/day, 450 mg/day, and 600 mg/day) and alprazolam (1.5 mg/day) in the treatment of 454 patients with GAD in a randomized, placebo-controlled, multi-site trial. All three doses of pregabalin and alprazolam were signifi cantly superior to placebo in reduction of HAM-A scores and separation from placebo was observed at week one for all treatments.
A recent double-blind comparison of pregabalin (400 mg/ day and 600 mg/day) and fi xed-dose venlafaxine (75 mg/day) found both dosages of pregabalin and venlafaxine produced signifi cantly greater improvement in HAM-A total score than did placebo (Montgomery et al 2006) . HAM-A scores at week one were signifi cantly greater than placebo for both dosages of pregabalin while venlafaxine-treated patients had statistically signifi cant improvement at week two (Montgomery et al 2006) Withdrawal effects of pregabalin in patients with anxiety disorders Of note, clinical trials of pregabalin in the treatment of generalized anxiety and social anxiety disorder have included withdrawal measures such as the physician withdrawal checklist (PWC), a physician-administered instrument which measures 20 common withdrawal symptoms and has been used extensively to evaluate benzodiazepine withdrawal (Rickels et al 1990) . Following 4 weeks of pregabalin treatment, Rickels and colleagues (2005) determined PWC scores during a 1-week taper and found similar PWC scores in all treatment groups (pregabalin 300 mg/day, 450 mg/day, and 600 mg/day; alprazolam 1.5 mg/day). However, in the subsequent week, during which subjects were medication free, signifi cantly higher withdrawal anxiety was observed in patients who had been treated with pregabalin 600 mg/day (p < 0.04 vs placebo) (Rickels et al 2005) . Interestingly, this study did not observe signifi cant increases in PWC scores in those patients who had been treated with alprazolam, 1.5 mg/day (Rickels et al 2005) . Pande et al (2003) found PWC scores to be signifi cantly higher than placebo for patients receiving lorazepam (6 mg/day) and noted a statistical trend (p = 0.06) for patients receiving pregabalin 600 mg/day to have increased discontinuation-related anxiety symptoms, but found no difference in PWC score between pregabalin 150 mg/day and placebo (Pande et al 2003) . Pohl et al (2005) found PWC scores following swift taper or abrupt discontinuation of pregabalin (200 mg/day) to be no different from placebo but found PWC scores to be higher than placebo in the patients who had been treated with pregabalin (450 mg/ day), though the authors of this study did not consider these differences to be clinically signifi cant (Pohl et al 2005) .
Effects of pregabalin on mood in GAD patients
Because depressive-spectrum disorders commonly co-occur in patients with GAD, and anxiolytics can sometimes worsen or improve depressive symptoms, several of the clinical trials have included measures of depressive symptoms. Pohl and colleagues (2003) observed improvement in Hamilton Depression (HAM-D) Scale (17-item) scores for patients receiving pregabalin 200 mg tid but did not observe such a difference for patients receiving pregabalin 150 mg/day (5.5 points) or lorazepam 6 mg/day (5.6 points). In a 6-week trial comparing pregabalin (400 mg/day and 600 mg/day) with fi xed-dose venlafaxine (75 mg/day) HAM-D scores were noted to improve (vs placebo) by 5.3 points (pregabalin 400 mg/day), 4.9 points (pregabalin 600 mg/day), and 5.1 points (venlafaxine 75 mg/day) (Montgomery et al 2006) . Rickels et al (2005) excluded patients with depression in their study but did not observe any worsening in HAM-D scores in patients receiving pregabalin (300 mg/day, 450 mg/day, or 600 mg/day) or alprazolam. Both Feltner et al (2003) and Pande et al (2003) excluded patients with current major depression, though patients with dysthymia or a history of major depression were enrolled. Neither of these studies noted worsening of depressive symptoms in any treatment arm, though it might be noted that the HAM-D lacks sensitivity for the detection of atypical depression.
Adverse effects and safety of pregabalin in patients with anxiety disorders
The most frequently reported adverse effects in GAD patients included dizziness, somnolence, headache, dry mouth, amblyopia, and diarrhea, all of which were more frequent in patients receiving pregabalin 600 mg/day compared with those receiving pregabalin 150 mg/day (Pande et al 2003; Feltner et al 2003) . A study of pregabalin 400 mg/day and 600 mg/day in GAD also found dizziness to be the most common side-effect, followed by somnolence (Montgomery et al 2006) . A dose-effect with respect to these side-effects was observed (Montgomery et al 2006) . Pohl and colleagues (2005) evaluated bid and tid dosing and found no signifi cant difference in side-effects, though the overall adverse effects were similar to those described in previous studies: dizziness, somnolence and dry mouth, but also euphoria, inco-ordination, fl atulence, and diffi culty concentrating (Pohl et al 2005) .
Given concern for somnolence and other possible central nervous system depressant effects, Hindmarch et al (2005) evaluated the cognitive and psychomotor effects of pregabalin (450 mg/day) compared with alprazolam (3 mg/day) and placebo in healthy volunteers. In this study pregabalin produced "only minor, transient impairment on some objective cognitive and psychomotor measures, suggesting a relatively benign CNS side-effect profi le", while alprazolam treatment resulted in signifi cant decrement in all measures (Hindmarch et al 2005) .
Weight gain has been associated with pregabalin in nearly all clinical trials of patients with anxiety disorders (Pande et al 2003 (Pande et al , 2004 Pohl et al 2005; Rickels et al 2005; Montgomery et al 2006) and appears to be a dose-related effect. In a 4-week trial, mean increases in weight (± SEM) were 1.1 ± 0.2 kg for patients receiving 300 mg, 1.4 ± 0. 2 kg for patients receiving 450 mg, and 1.9 ± 0.3 kg for patients taking 600 mg, while increases of 0.9 ± 0.3 kg were observed for patients taking alprazolam (1.5 mg/day); all increases in weight were statistically signifi cant compared with placebo (Rickels et al 2005) . Pande et al (2003) similarly observed signifi cant weight increases of 1.3 kg and 2.2 kg in patients treated for 4 weeks with pregabalin 150 mg/day and 600 mg/day respectively, but did not observe signifi cant weight gain in patients treated with lorazepam (Pande et al 2003) . The studies by Montgomery et al (2006) and Feltner et al (2003) noted that some pregabalin-treated patients did experience >7% increases in body mass but do not include statistical comparisons with placebo-treated patients. Finally, Pande et al observed mean increases of 0.6 kg and 1.7 kg in patients receiving pregabalin 150 mg/day and 600 mg/day for 4 weeks respectively, while patients treated with placebo had a mean weight loss of 0.1 kg; however, no statistical comparisons were reported (Pande et al 2004) . The effects of pregabalin on lipid profi les are unknown.
Discussion
In a disorder that is often suboptimally responsive to traditional psychotherapeutic and psychopharmacologic interventions -secondary to poor effi cacy, tolerability, and/or side-effects -pregabalin may have an emerging role in the treatment of GAD. Moreover, pregabalin may have a primary role in patients with certain psychiatric comorbidities (eg, bipolar disorder, substance dependence) and in patients with multiple medical comorbidities who may be taking multiple concomitant medications, as pregabalin has no known drug interactions (Brodie et al 2005; Pfi zer Inc. 2006) .
The effi cacy of pregabalin in treating GAD is not surprising as a number of other antiepileptic drugs have also been shown to have anxiolytic properties and to be effective in treating patients with anxiety disorders. Valproate has been shown to have effi cacy in the treatment of panic disorder (Primeau et al 1990; Woodman and Noyes 1994; Baetz and Bowen 1998) and blocks lactate-induced panic attacks (Keck et al 1993) . The antiepileptic drug carbamazepine has efficacy in the treatment of panic disorder (Tondo et al 1989) , post-traumatic stress disorder (PTSD) (Lipper et al 1986) , and obsessive compulsive disorder (OCD) (Joffe and Swinson 1987) . Lamotrigine is potentially effective in the treatment of PTSD (Hertzberg et al 1999) and may have an adjunctive role in the treatment of refractive OCD (Kumar and Khanna 2000) . Topiramate has been shown to be effi cacious in open-label trials for PTSD (Berlant and van Kammen 2002; Berlant 2004) , social phobia disorder (Van Ameringen et al 2004) and may have an adjunctive role in treatment-resistant OCD (Van Ameringen et al 2006) . However, unlike previous antiepileptic drugs which primarily block sodium and potassium channels or increase cerebral GABA concentrations, pregabalin decreases presynaptic Abbreviations: GAD, generalized anxiety disorder; LOCF, last observation carried forward.
calcium currents and in doing so decreases the release of several neurotransmitters, including glutamate (Dooley et al 2000a) , substance P (Fehenbacher et al 2003) , calcitoningene-related peptide (Fehenbacher et al 2003) , and norepinephrine (Dooley et al 2002) . Interestingly, many of these neurotransmitters have been implicated in the pathogenesis GAD or other anxiety disorders (Erikkson et al 1991; Geracioti et al 2001; Olsson et al 2004; Geracioti et al 2006) . As might be expected, agents that pharmacologically dampen these systems have therapeutic roles in a number of anxiety disorders (Peet and Ali 1986; Furmark et al 2005; Strawn and Geracioti 2006) . Also, decreases in the activity of these or related "fear circuits" that underlie the pathophysiology of certain anxiety disorders (Stahl 2004) could explain the effi cacy of pregabalin in patients with GAD. It will be of interest to examine the effects of pregabalin in other anxiety disorders such as PTSD, panic disorder, or even meal-related anxiety in anorexia nervosa (wherein additional benefi t may be conferred by pregabalin-associated weight gain).
Conclusion
Based entirely on data from industry-sponsored (Pfi zer), multi-site clinical trials, pregabalin appears to be generally well-tolerated in adult patients with generalized anxiety disorder and has rapid onset of action (approximately one week) as well as comparable effi cacy to benzodiazepines Rickels et al 2005) . Moreover, discontinuation rates observed in the fi ve published double-blind, placebocontrolled trials of pregabalin in the treatment of GAD have generally been lower than those observed for both benzodiazepines (Geltner et al 2003; Pande et al 2003; Rickels et al 2005) and venlafaxine, 75 mg/day (Montgomery et al 2006) .
